Webinar: Lumipulse® G KL-6, the biomarker for routinely assessment of epithelial alveolar damage in pulmonary fibrosis and COVID-19
During this webinar
- Dr. Francesco Bonella (MD)
Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University Hospital, Essen, Germany, - Dr. Elena Bargagli (MD)
Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences and Neurosciences, Siena University Hospital, Siena, Italy, - Dr. Diego Castillo (MD)
Pneumology and Allergy Service of the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain and - Dr. Miriana d'Alessandro (PhD, Biologist)
Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences and Neurosciences, Siena University Hospital, Siena, Italy
discussed the latest information on the role of KL-6 in the management of patients at high risk of developing Acute Respiratory Distress Syndrome (ARDS) as well as in the evaluation of residual fibrosis as a result of acute lung injury (ALI) after COVID-19 infection.
View the complete webinar below:
About Krebs von den Lungen (KL-6):
KL-6 is a mucin-like glycoprotein expressed on the surface membrane of alveolar epithelial cells (AEC) and bronchiolar epithelial cells.
Type II AEC are centrally involved in the pathobiology of Interstitial Lung Diseases (ILD). Serum KL-6 reflects AEC-II injury by direct leakage through the interstitium to the bloodstream.
KL-6 is also showing evolving evidence as a valuable tool in the current COVID-19 pandemic to aid in early identification of patients at high risk of developing Acute Respiratory Distress Syndrome (ARDS) as well as assist in the evaluation of residual fibrosis as a result of acute lung injury (ALI) after COVID-19 infection.
Find many more resources about KL-6 at www.fujirebio.com/kl-6
Related articles
[Jan 2022 Update] This scientific literature overview demonstrates the excellent performance of the fully automated nucleocapsid protein antigen assay Lumipulse® G SARS-CoV-2 Ag
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
I...
Japanese authorities have chosen Lumipulse® for nasopharyngeal or saliva-based SARS-CoV-2 antigen testing of passengers at their main international airports
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
Can KL-6 be a specific marker of alveolar damage for COVID-19 patients?
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...
From Classification to disease activity
While IPF is the classic fibrosing ILD, clinical data suggest that there is a larger group of patients with differing clinical ILD diagnoses who...
KL-6 in disease prognosis
Recent research has shown that serum and bronchoalveolar lavage fluid level of KL-6 has an important value in the diagnosis, treatment assessment and...
Use of serum biomarkers in progressive fibrosing ILDs
Based on the results from a number of reports investigating KL-6/MUC1, the serum levels of KL-6/MUC1 are useful for 1) detecting the presence of...
ILD diagnosis – current professional practice
Accurate diagnosis of IPF is critical, as other forms of ILD that have similar clinical presentations to IPF require different treatment strategies.
KL-6 in Lung Diseases: Current classification of interstitial lung diseases
Interstitial lung diseases (ILDs) represent a large, heterogeneous group of more than 200 different entities, most of which are classified as rare...
Mesothelin, the novel, non-invasive in vitro biomarker to aid in the diagnosis of Mesothelioma
Mesothelioma is a rare form of cancer that is linked to exposure to asbestos. Although malignant mesothelioma remains a relatively uncommon malignancy...
Powered by Bioz
